welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
Dyne Therapeutics Announces Equity Investment from CureDuchenne Ventures to Support Pioneering Approach to Restoring Muscle Health in DMD
WALTHAM, Mass., March 31, 2020 – Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced an equity
investment from CureDuchenne Ventures. The funding will support Dyne’s development of precision therapeutics designed to restore muscle health in people living with Duchenne muscular dystrophy (DMD).
“Dyne’s partnership with CureDuchenne underscores our deep commitment and our sense of urgency as we work to bring life-transforming therapies to patients living with DMD and other serious muscle disorders. We appreciate the collaboration with and investment from CureDuchenne Ventures, which will help us advance our novel approach to targeting the genetic basis of DMD, with the goal of halting disease progression and restoring muscle health,” said Joshua Brumm, Dyne’s president and chief executive officer. “We look forward to continuing to collaborate with CureDuchenne and all of our partners in the Duchenne community. Together, we will improve the lives of those impacted by this devastating disease.”
rareRelated
-
Preliminary Data and Intention to Dose Escalate in IGNITE DMDToday we announced our intention to move...
-
Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License AgreementEli Lilly and Company and Precision BioS...
-
Nationwide Children’s Hospital Begins New First-in-Human Clinical Study for DMD Using a Novel Gene Therapy Approac...CureDuchenne is very proud that Dr. Kevi...
-
First Patient Dosed in Phase II Clinical Trial in Duchenne Muscular DystrophyAntisense Therapeutics today announced d...
-
Jerry Mendell, M.D., Presented Positive Updated Results from the Four Children Dosed in the Gene Therapy Micro-dystr...Sarepta Therapeutics, Inc., a commercial...
-
ReveraGen Announces First Patient Enrollment in International Pivotal Trial of Vamorolone in Duchenne Muscular Dystr...ReveraGen BioPharma, Inc. today announce...
-
cTAP Study Shows Real-World, Natural History Data Comparable To Placebo Data From Clinical Trials In Duchenne Muscul...CAMBRIDGE, Mass., Sept. 8, 2020 /PRNew...
